Hiroe Niwano Selected Research

Atrial Remodeling

1/2021	Canagliflozin Suppresses Atrial Remodeling in a Canine Atrial Fibrillation Model.
8/2019	Liraglutide suppresses atrial electrophysiological changes.
10/2018	Linagliptin prevents atrial electrical and structural remodeling in a canine model of atrial fibrillation.
9/2018	Antiremodeling Effect of Xanthine Oxidase Inhibition in a Canine Model of Atrial Fibrillation.
1/2017	Aliskiren suppresses atrial electrical and structural remodeling in a canine model of atrial fibrillation.
2/2014	Effect of carvedilol on atrial remodeling in canine model of atrial fibrillation.
1/2014	Cardiomyocyte-derived mitochondrial superoxide causes myocardial electrical remodeling by downregulating potassium channels and related molecules.
5/2012	Combined effects of up- and downstream therapies on atrial fibrillation in a canine rapid stimulation model.
4/2008	Neutral endopeptidase inhibitor suppresses the early phase of atrial electrical remodeling in a canine rapid atrial pacing model.
2/2008	Inhomogenic effect of bepridil on atrial electrical remodeling in a canine rapid atrial stimulation model.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hiroe Niwano Research Topics

Disease

13	Atrial Fibrillation 01/2021 - 07/2009
13	Atrial Remodeling 01/2021 - 02/2006
6	Myocarditis (Carditis) 01/2012 - 01/2002
5	Fibrosis (Cirrhosis) 10/2018 - 02/2008
3	Heart Failure 01/2015 - 01/2012
2	Dilated Cardiomyopathy (Cardiomyopathy, Congestive) 05/2016 - 05/2002
2	Ventricular Remodeling 01/2011 - 01/2011
2	Cardiac Arrhythmias (Arrythmia) 01/2011 - 05/2010
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2021
1	Epilepsy (Aura) 08/2016
1	Shock 05/2016
1	Supraventricular Tachycardia 05/2016
1	Tachycardia (Tachyarrhythmias) 05/2016
1	Ischemia 01/2012
1	Torsades de Pointes (Torsade de Pointes) 05/2010
1	Hypertrophy 05/2006
1	Heart Diseases (Heart Disease) 05/2006
1	Thrombotic Microangiopathies 01/2005
1	Spasm (Spasms) 03/2003
1	Myocardial Infarction 05/2002
1	Infarction (Infarctions) 05/2002
1	Body Weight (Weight, Body) 05/2002

Drug/Important Bio-Agent (IBA)

4	Bepridil (Vascor)FDA Link 01/2011 - 02/2006
4	Messenger RNA (mRNA)IBA 01/2011 - 01/2002
3	Pharmaceutical PreparationsIBA 09/2018 - 05/2002
2	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 08/2019 - 10/2018
2	Reactive Oxygen Species (Oxygen Radicals)IBA 09/2018 - 01/2011
2	Adenosine Triphosphate (ATP)IBA 05/2016 - 01/2012
2	Cardiac MyosinsIBA 08/2006 - 05/2002
1	Sodium-Glucose Transport ProteinsIBA 01/2021
1	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2021
1	CanagliflozinIBA 01/2021
1	Glucagon-Like Peptide 1 (GLP 1)IBA 08/2019
1	LinagliptinIBA 10/2018
1	Xanthine OxidaseIBA 09/2018
1	Febuxostat FDA Link 09/2018
1	Fibronectins (Fibronectin)IBA 09/2018
1	AntioxidantsIBA 09/2018
1	aliskiren FDA Link 01/2017
1	Sodium Channels (Sodium Channel)IBA 08/2016
1	Anticonvulsants (Antiepileptic Drugs)IBA 08/2016
1	NF-kappa B (NF-kB)IBA 01/2015
1	Mitogen-Activated Protein KinasesIBA 01/2015
1	RivaroxabanIBA 01/2015
1	Carvedilol (Coreg)FDA LinkGeneric 02/2014
1	Potassium Channels (Potassium Channel)IBA 01/2014
1	Buthionine SulfoximineIBA 01/2014
1	Superoxides (Superoxide)IBA 01/2014
1	Superoxide DismutaseIBA 01/2014
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2013
1	Connective Tissue Growth FactorIBA 08/2012
1	Angiotensin IIIBA 08/2012
1	Angiotensin Receptor AntagonistsIBA 05/2012
1	Connexin 43 (Connexin43)IBA 05/2012
1	mitochondrial K(ATP) channelIBA 01/2012
1	Mexiletine (Mexitil)FDA LinkGeneric 01/2012
1	CalciumIBA 01/2012
1	Nicorandil (SG 75)IBA 01/2012
1	Acetylcysteine (Siran)FDA LinkGeneric 01/2011
1	Glutathione (Reduced Glutathione)IBA 01/2011
1	Anti-Arrhythmia AgentsIBA 05/2010
1	pilsicainideIBA 07/2009
1	Neprilysin (Neutral Endopeptidase)IBA 04/2008
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 02/2008
1	ConnexinsIBA 02/2008
1	Ion Channels (Ion Channel)IBA 02/2008
1	Atrial Natriuretic Factor (ANF)IBA 01/2008
1	Immunologic Factors (Immunomodulators)IBA 08/2006
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 05/2006
1	CytokinesIBA 05/2006
1	Mitomycin (Mitomycin-C)FDA LinkGeneric 01/2005
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2005
1	Acetylcholine (Acetylcholine Chloride)FDA Link 03/2003
1	Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA 03/2003
1	Pentoxifylline (Trental)FDA LinkGeneric 05/2002
1	Protein Isoforms (Isoforms)IBA 05/2002
1	Proteins (Proteins, Gene)FDA Link 05/2002
1	Phosphodiesterase InhibitorsIBA 05/2002
1	Ribonucleases (Ribonuclease)IBA 01/2002

Therapy/Procedure

4	Therapeutics 08/2016 - 08/2006
1	Implantable Defibrillators (Implantable Cardioverter-Defibrillator) 05/2016
1	Induced Hypothermia 05/2016
1	Patient Readmission 07/2012